指南与共识妇科肿瘤

宫颈上皮内瘤变2级的主动监测:2025年英国阴道镜与宫颈病理学会及欧洲妇科肿瘤学会共识声明

Active surveillance of cervical intraepithelial neoplasia grade 2: 2025 British Society of Colposcopy and Cervical Pathology and European Society of Gynaecologic Oncology consensus statement.
指南 / 共识 · Lancet Oncol · 2025-01-01

该共识声明由英国阴道镜与宫颈病理学会与欧洲妇科肿瘤学会预防委员会制定,旨在为宫颈上皮内瘤变2级(CIN2)的主动监测提供推荐。声明指出约50-60%的CIN2可自发消退,主动监测在部分患者中可能合理,但需权衡进展风险与消退获益,并考虑年龄、生育意愿等因素。

要点

  • 约50-60%的CIN2病变可自发消退,主动监测在部分患者中可能合理。
  • 2023年发现主动监测患者20年浸润癌累积风险高于立即局部治疗者,差异在30岁以上女性最大。
  • 需临床审计及前瞻性数据库监测长期结局与安全性。

核心结论

  • 在精心选择的部分患者中,主动监测而非立即治疗可能是合理的。
  • 需仔细权衡主动监测相关的进展风险、重复就诊需求及未来浸润累积风险与等待消退的获益。

研究设计与样本

  • 英国阴道镜与宫颈病理学会和欧洲妇科肿瘤学会预防委员会制定的政策综述与实践算法。

主要发现

  • 过去十年证据提示50-60%的CIN2病变可自发消退。
  • 2023年发现主动监测患者20年浸润癌累积风险显著高于立即局部治疗者,差异在30岁以上女性最大。

关键数值与推荐

  • 主动监测的资格、监测频率、治疗阈值及恢复常规随访的标准在多数国家尚不充分。
  • 考虑因素包括女性年龄、生育意愿、其他危险因素及随访依从性可能性。

临床怎么用

  • 主动监测而非立即治疗在精心选择的部分患者中可能合理。
  • 需临床审计及理想的前瞻性数据库监测长期结局与安全性。

局限性

  • 主动监测的资格、监测频率、治疗阈值及恢复常规随访的标准在多数国家尚不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Histological diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2) has traditionally been the cutoff for local surgical treatment, due to a substantial risk of cancer development. However, evidence from the past decade suggests 50-60% of CIN2 lesions spontaneously regress, and active surveillance (or conservative management-ie, leaving the lesion untreated) might be justified in some cases. Active surveillance of CIN2 lesions is now practised widely, although clear recommendations on eligibility, frequency of surveillance, threshold for treatment, and criteria for return to routine recall are insufficient in most countries. In 2023, the cumulative risk of invasive cancer over 20 years was found to be substantially higher in patients under active surveillance when compared with patients who received immediate local treatment, with the greatest difference observed in women older than 30 years. This Policy Review and practice algorithm from the British Society of Colposcopy and Cervical Pathology and the European Society of Gynaecologic Oncology prevention committees aims to review existing evidence and present clear recommendations to assist clinical decision making. Active surveillance, rather than immediate treatment, might be reasonable in a carefully selected cohort of patients. The risk of progression, need for repeat visits, and cumulative risk of future invasion associated with active surveillance should be carefully balanced against the benefits of awaiting regression, including consideration of the woman's age, fertility wishes, additional risk factors, and likelihood of compliance to follow-up. Clinical audit and, ideally, prospective databases are required to monitor long-term outcomes and safety.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kyrgiou M, Bowden SJ, Ellis LB, et al. Active surveillance of cervical intraepithelial neoplasia grade 2: 2025 British Society of Colposcopy and Cervical Pathology and European Society of Gynaecologic Oncology consensus statement. Lancet Oncol. 2025. PMID: 40049205. doi:10.1016/S1470-2045(24)00524-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。